Floatz logo

Modotuximab

Solid Tumors

Merck KGaA, Darmstadt, Germanymonoclonal_antibodyPhase 1Dormant
C
33/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
65/ 100

Competitive context

208 Active assets in the Solid Tumors cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Hellenic Society of Hematology
Phase 3BB
FILGRASTIM
Ankara Etlik City Hospital
Phase 2BB
Carboplatin
Bristol-Myers Squibb
Phase 3BB
Ribociclib
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 4B
Irinotecan
Mirati Therapeutics Inc.
Phase 3B

View all 50 →

Same molecule, other indications

Modotuximab is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
47 / 100
View asset →
Colorectal Cancer MetastaticDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →